Neuro-Oncology News

Direct oral anticoagulants did not appear associated with a higher incidence of intracranial hemorrhage compared with low-molecular-weight heparin in patients with brain metastases or primary brain tumors, according to results of a retrospective study published in Journal of Thrombosis and Haemostasis.

Robert M. Prins , PhD, received a $750,000 grant from Brain Tumor Funders’ Collaborative to support his research of immunotherapies for brain tumors.

A vaccine that targets the protein survivin appeared safe and extended survival among patients with newly diagnosed glioblastoma, according to results from a phase 2 study presented at Society for Neuro-Oncology Annual Meeting.

A test that identifies genetic mutations in the blood accurately detected a specific type of pediatric diffuse midline glioma that is associated with poorer clinical outcomes, according to study results.

Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

Regorafenib conferred an encouraging OS benefit compared with lomustine among patients with recurrent glioblastoma, according to a randomized, open-label phase 2 study published in The Lancet Oncology.

On Nov. 26, the FDA announced the accelerated approval of larotrectinib as the first small molecule inhibitor for use in a “cancer-agnostic” manner, in pediatric and adult human cancers that harbor neurotrophic receptor tyrosine kinase gene fusions.

The overall rate of cancer deaths in the U.S. has declined by 27% during the past 25 years, with approximately 2.6 million fewer cancer deaths reported between 1991 and 2016, according to data from Cancer Statistics 2019, American Cancer Society’s annual report on cancer rates and trends.

Linda M. Liau, MD, PhD, MBA, received the Abhijit Guha Award in recognition of her work treating brain tumors.

The NIH awarded a 5-year, $693,000 grant to The Feinstein Institute for Medical Research to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children and plan for the future.